Genetics and biology of pancreatic ductal adenocarcinoma

Genes and Development

Volumn 30, Issue 4, 2016, Pages 355-385

  Ying, Haoqiang ^a   Dey, Prasenjit ^a   Yao, Wantong ^a   Kimmelman, Alec C ^b   Draetta, Giulio F ^a   Maitra, Anirban ^a   Depinho, Ronald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cancer metabolism; KRAS; Pancreatic cancer; Tumor immune modulation

Indexed keywords

ADVANCED CANCER; CANCER CELL; CANCER GENETICS; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CELL METABOLISM; DNA DAMAGE; DNA DAMAGE REPAIR; DNA REPAIR; EARLY DIAGNOSIS; EPIGENETICS; GENE MUTATION; GENOME; GLUCOSE METABOLISM; HUMAN; IMMUNOREGULATION; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROMA; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; VALIDATION STUDY; CARCINOMA, PANCREATIC DUCTAL; GENETICS; IMMUNOLOGY; PANCREATIC NEOPLASMS; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

KRAS PROTEIN, HUMAN; PROTEIN P21;

CARCINOMA, PANCREATIC DUCTAL; HUMANS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84958973412     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.275776.115     Document Type: Review

References (394)

1. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. 2003. Activated Kras and Ink4a/ Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112-3126.
2. Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, Leo C, Zhang Y, Zhang J, Gans JD, Bardeesy N, et al. 2004. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci 101: 9067-9072.
3. Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, et al. 2015. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res 21: 396-404.
4. Alexandrov LB, Nik-Zainal S,Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. 2013. Signatures of mutational processes in human cancer. Nature 500: 415-421.
5. Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, et al. 2015. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res 21: 1360-1372.
6. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. 2007. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117: 326-336.
7. Ancrile B, Lim K-H, Counter CM. 2007. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 1714-1719.
8. Andea A, Sarkar F, Adsay VN. 2003. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 16: 996-1006.
9. Andersen DK. 2013. Diabetes and cancer: placing the association in perspective. Curr Opin Endocrinol Diabetes Obes 20: 81-86.
10. ApteMV,Wilson JS. 2012. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J Gastroenterol Hepatol 27: 69-74.
11. Apte MV, Pirola RC, Wilson JS. 2012. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol 3: 344.
12. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, et al. 2012. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22: 304-317.
13. Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, et al. 2015. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the 'THERAPY' phase 1-2 trial. Oncotarget 6: 12796-12808.
14. Baek G, Tse YF, Hu Z, Cox D, Buboltz N, McCue P, Yeo CJ, White MA, DeBerardinis RJ, Knudsen ES, et al. 2014. MCT4defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep 9: 2233-2249.
15. Baer R, Cintas C, Dufresne M, Cassant-Sourdy S, Schonhuber N, Planque L, Lulka H, Couderc B, Bousquet C, Garmy-Susini B, et al. 2014. Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wildtype PI 3-kinase p110α. Genes Dev 28: 2621-2635.
16. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA. 2008. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 14: 5995-6004.
17. Bailey JM, Mohr AM, Hollingsworth MA. 2009. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene 28: 3513-3525.
18. Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, et al. 2014. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 146: 245-256.
19. Bailey JM, HendleyAM, Lafaro KJ, Pruski MA, Jones NC, Alsina J, Younes M, Maitra A, McAllister F, Iacobuzio-Donahue CA, et al. 2015. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. Oncogene doi: 10.1038/onc.2015.441.
20. Bailey P, Chang DK, Nones K, Johns AL, Patch A, Gingras M, Miller DK, Christ AN, Bruxner TJC, Quinn MC, et al. 2016. The molecular pathology of pancreatic cancer. Nature (in press).
21. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, et al. 2006a. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci 103: 5947-5952.
22. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, et al. 2006b. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20: 3130-3146.
23. Bardelli A, Siena S. 2010. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254-1261.
24. Bar-Sagi D, Feramisco JR. 1986. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 233: 1061-1068.
25. Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, Brosens LA, Fukushima N, Goggins M, Hruban RH, et al. 2015. A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39: 1730-1741.
26. Baumgart S, Ellenrieder V, Fernandez-Zapico ME. 2013. Oncogenic transcription factors: cornerstones of inflammationlinked pancreatic carcinogenesis. Gut 62: 310-316.
27. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH. 2012. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21: 822-835.
28. Beatty GL, O'Hara MH, Nelson AM, McGarvey M, Torigian DA, Lacey SF, Melenhorst JJ, Levine B, Plesa G, June CH. 2015. Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. J Clin Oncol 33: 3007.
29. Becker AE, Hernandez YG, Frucht H, Lucas AL. 2014. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol 20: 11182-11198.
30. Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Perez-Garcia J, Stathis A, Britten CD, et al. 2015. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res 21: 730-738.
31. Bellone G, Carbone A, Smirne C, ScirelliT, Buffolino A, Novarino A, Stacchini A, Bertetto O, Palestro G, Sorio C, et al. 2006a. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol 177: 3448-3460.
32. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M, Emanuelli G. 2006b. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 55: 684-698.
33. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR,Watkins DN, et al. 2003. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425: 846-851.
34. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. 2014. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6: 224ra224.
35. Biankin AV,Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, et al. 2012. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399-405.
36. BijlsmaMF, van LaarhovenHW. 2015. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer Metastasis Rev 34: 97-114.
37. Bissell MJ, Radisky D. 2001. Putting tumours in context. Nat Rev Cancer 1: 46-54.
38. Biswas SK. 2015. Metabolic reprogramming of immune cells in cancer progression. Immunity 43: 435-449.
39. Biswas SK, Mantovani A. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889-896.
40. Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J, Baccarini M, Barbacid M. 2011. c-Raf, but not BRaf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19: 652-663.
41. Bogdan C. 2001. Nitric oxide and the immune response. Nat Immunol 2: 907-916.
42. Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA, et al. 2015. Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Ann Surg Oncol 22: 4402-4410.
43. Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS, et al. 1997. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 57: 4242-4248.
44. Boros LG, Lee WN, Go VL. 2002. A metabolic hypothesis of cell growth and death in pancreatic cancer. Pancreas 24: 26-33.
45. Boroughs LK, DeBerardinis RJ. 2015. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 17: 351-359.
46. Brahmer JR, Drake CG,Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175.
47. + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162: 5728-5737.
48. Brune K, Abe T, Canto M, O'Malley L, Klein AP, Maitra A, Volkan Adsay N, Fishman EK, Cameron JL, Yeo CJ, et al. 2006. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 30: 1067-1076.
49. Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. 2011. Targeting regulatory T cells in cancer. Cancer Res 71: 6915-6920.
50. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, et al. 2013. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62: 339-347.
51. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. 2007. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27: 635-646.
52. Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, Moore C, Kumar MS, Murillo MM, Gronroos E, et al. 2013. Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 24: 617-630.
53. Cebola I, Rodriguez-Segui SA, Cho CH, Bessa J, Rovira M, Luengo M, Chhatriwala M, Berry A, Ponsa-Cobas J, Maestro MA, et al. 2015. TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors. Nat Cell Biol 17: 615-626.
54. Chandra A, Grecco HE, Pisupati V, Perera D, Cassidy L, Skoulidis F, Ismail SA, Hedberg C, Hanzal-Bayer M, Venkitaraman AR, et al. 2012. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol 14: 148-158.
55. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van derWindt GJ, et al. 2015. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162: 1229-1241.
56. Chen L,Lei L,Chang X,Li Z,Lu C,Zhang X,Wu Y,Yehl T,Zhong G. 2010. Mice deficient in MyD88 develop a Th2-dominant responseandseverepathologyintheuppergenital tract following Chlamydia muridaruminfection. J Immunol 184: 2602-2610.
57. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. 2007. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67: 9518-9527.
58. Cleary AS, Leonard TL, Gestl SA, Gunther EJ. 2014. Tumour cell heterogeneity maintained by cooperating subclones in Wntdriven mammary cancers. Nature 508: 113-117.
59. Coffelt SB, de Visser KE. 2014. Cancer: inflammation lights the way to metastasis. Nature 507: 48-49.
60. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M. 2012. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122: 639-653.
61. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J,Weinkle J, Kim GE, Jakkula L, et al. 2011. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17: 500-503.
62. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, et al. 2012. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2: 685-693.
63. Colombo MP, Piconese S. 2007. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7: 880-887.
64. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, et al. 2013. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497: 633-637.
65. Cox AD, Olive KP. 2012. Silencing the killers: paracrine immune suppression in pancreatic cancer. Cancer cell 21: 715-716.
66. Cox AD, Der CJ, Philips MR. 2015. Targeting RAS membrane association: back to the future for anti-RAS drug discovery? Clin Cancer Res 21: 1819-1827.
67. Cseh B, Doma E, Baccarini M. 2014. 'RAF' neighborhood: protein- protein interaction in the Raf/Mek/Erk pathway. FEBS Lett 588: 2398-2406.
68. Cubilla AL, Fitzgerald PJ. 1976. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 36: 2690-2698.
69. da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. 2010. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 116: 5599-5607.
70. Dal Molin M, Matthaei H,WuJ, Blackford A, Debeljak M, Rezaee N, Wolfgang CL, Butturini G, Salvia R, Bassi C, et al. 2013. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg Oncol 20: 3802-3808.
71. Dang CV. 2012. Links between metabolism and cancer. Genes Dev 26: 877-890.
72. Day CP, Merlino G, Van Dyke T. 2015. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell 163: 39-53.
73. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. 2008. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18: 54-61.
74. Delgiorno KE, Hall JC, Takeuchi KK, Pan FC, Halbrook CJ,Washington MK, Olive KP, Spence JR, Sipos B, Wright CV, et al. 2014. Identification and manipulation of biliary metaplasia in pancreatic tumors. Gastroenterology 146: 233-244.e5.
75. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. 2011. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208: 469-478.
76. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, et al. 2011. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109.
77. Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, et al. 2015. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut doi: 10.1136/gutjnl-2015-309193.
78. Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I. 2012. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas 41: 1001-1007.
79. Downward J. 2015. RAS synthetic lethal screens revisited: still seeking the elusive prize? Clin Cancer Res 21: 1802-1809.
80. Du J, Nelson ES, Simons AL, Olney KE, Moser JC, Schrock HE, Wagner BA, Buettner GR, Smith BJ, Teoh ML, et al. 2013. Regulation of pancreatic cancer growth by superoxide. Mol Carcinog 52: 555-567.
81. Efeyan A, Comb WC, Sabatini DM. 2015. Nutrient-sensing mechanisms and pathways. Nature 517: 302-310.
82. Eng CH,Wang Z, Tkach D, Toral-Barza L, Ugwonali S, Liu S, Fitzgerald SL, George E, Frias E, Cochran N, et al. 2016. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc Natl Acad Sci 113: 182-187.
83. Eser S, Messer M, Eser P, von Werder A, Seidler B, Bajbouj M, Vogelmann R, Meining A, von Burstin J, Algul H, et al. 2011. In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc Natl Acad Sci 108: 9945-9950.
84. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, et al. 2013. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23: 406-420.
85. Ezernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E, Halabi A, Pikarsky E, Shapira L, Baniyash M. 2006. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 177: 4763-4772.
86. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, et al. 2008. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5: e123.
87. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, et al. 2011. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475: 226-230.
88. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, et al. 2013. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci 110: 20212- 20217.
89. Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, Goggins M, Maitra A, Nelkin BD. 2010. Inhibiting the cyclin- dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 70: 4460-4469.
90. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, et al. 2006. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 32: 22-28.
91. Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, Ruggero D, McCormick F. 2015. EnhancedMETtranslation and signaling sustains K-Ras-driven proliferation under anchorage-independent growth conditions. Cancer Res 75: 2851-2862.
92. Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, et al. 2013. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer 132: 785-794.
93. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. 2001. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166: 5398-5406.
94. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G, Chiaradonna F. 2011. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 7: 523.
95. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, et al. 2015. Autophagy in malignant transformation and cancer progression. EMBO J 34: 856-880.
96. Garcia-Carracedo D, Turk AT, Fine SA, Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger JM, Remotti HE, et al. 2013. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 19: 6830-6841.
97. Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E, DePinho RA, Jacks T. 2009. Contextdependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16: 379-389.
98. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. 2011. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17: 6985-6991.
99. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, et al. 1996. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56: 5360-5364.
100. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174: 1783-1786.
101. Gorrini C, Harris IS, Mak TW. 2013. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12: 931-947.
102. Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, Jeng HH, Bar-Sagi D. 2014. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25: 243-256.
103. Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, Petersen GM, Lerner-Ellis J, Holter S, Gallinger S. 2015. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148: 556-564.
104. Greer JB, Whitcomb DC. 2009. Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 9: 411-418.
105. Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, et al. 2014. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. J Clin Invest 124: 1794-1809.
106. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, Dubus P, Sandgren EP, Barbacid M. 2007. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302.
107. Guillaumond F, Bidaut G, Ouaissi M, Servais S, Gouirand V, Olivares O, Lac S, Borge L, Roques J, Gayet O, et al. 2015. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci 112: 2473-2478.
108. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, et al. 2015. Bruton's tyrosine kinase (BTK)-dependent immune cell crosstalk drives pancreas cancer. Cancer Discov doi: 10.1158/2159-8290.CD-15-0827.
109. Guo JY, White E. 2013. Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS (G12D)-driven lung tumors. Autophagy 9: 1636-1638.
110. Guo JY, ChenHY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V, et al. 2011. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 25: 460-470.
111. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, et al. 2013. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 27: 1447-1461.
112. Gupta S, Ramjaun AR, Haiko P,Wang Y,Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J. 2007. Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
113. Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, Feldmann G, Stoffers DA, Konieczny SF, Leach SD, et al. 2008. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci 105: 18913-18918.
114. Haber DA, Velculescu VE. 2014. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4: 650-661.
115. Hanahan D, Coussens LM. 2012. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309-322.
116. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
117. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, et al. 2013. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 23: 302-315.
118. Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, Kloeppel G, Rocken C, Bitzer M, Boeck S, et al. 2012. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 106: 1033-1038.
119. Helming KC,Wang X, RobertsCW. 2014a. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 26: 309-317.
120. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, et al. 2014b. ARID1B is a specific vulnerability in ARID1Amutant cancers. Nat Med 20: 251-254.
121. Hensley CT, Wasti AT, DeBerardinis RJ. 2013. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 123: 3678-3684.
122. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. 2007. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
123. Hermano E, Meirovitz A, Meir K, Nussbaum G, Appelbaum L, Peretz T, Elkin M. 2014. Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. J Natl Cancer Inst 106: dju332.
124. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA. 2006. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249.
125. Hidalgo M. 2010. Pancreatic cancer. N Engl J Med 362: 1605- 1617.
126. Hill R, Calvopina JH, Kim C,Wang Y, DawsonDW, Donahue TR, Dry S, Wu H. 2010. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 70: 7114-7124.
127. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450.
128. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, et al. 2014. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci 111: 3128-3133.
129. Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. 2014. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int 13: 371-380.
130. Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, Akbari M, Moore M, et al. 2015. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33: 3124-3129.
131. Hori M, Takahashi M, Hiraoka N, Yamaji T, Mutoh M, Ishigamori R, Furuta K, Okusaka T, Shimada K, Kosuge T, et al. 2014. Association of pancreatic Fatty infiltration with pancreatic ductal adenocarcinoma. Clin Transl Gastroenterol 5: e53.
132. Houot R, Schultz LM, Marabelle A, Kohrt H. 2015. T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res 3: 1115-1122.
133. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, BiankinAV, Biankin SA, Compton C, Fukushima N, Furukawa T, et al. 2004. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28: 977-987.
134. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, et al. 2006. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66: 95-106.
135. Hruban RH, Pitman MB, Klimstra DS. 2007. Tumors of the pancreas. AFIP atlas of tumor pathology, 4th series. American Registry of Pathology, Armed Forces Institute of Pathology, Washington, DC.
136. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, et al. 2012. K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 22: 399-412.
137. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131.
138. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, et al. 2014. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 28: 1800-1814.
139. Huen MS, Sy SM, Chen J. 2010. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 11: 138-148.
140. + T cells against NY-ESO-1. N Engl J Med 358: 2698-2703.
141. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. 2015. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res 13: 1325-1335.
142. Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM III, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, et al. 2015. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 33: 4039-4047.
143. Husain Z, Huang Y, Seth P, Sukhatme VP. 2013. Tumor-derived lactate modifies antitumor immune response: effect on myeloid- derived suppressor cells and NK cells. J Immunol 191: 1486-1495.
144. Hwang RF, Moore T, ArumugamT, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. 2008. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68: 918-926.
145. IhleNT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, et al. 2012. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 104: 228-239.
146. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. 1997. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649-1652.
147. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, WangW, Kan Z, Dbouk HA, Peters BA, Waring P, et al. 2009. Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell 16: 463-474.
148. Jameson KL, Mazur PK, Zehnder AM, Zhang J, Zarnegar B, Sage J, Khavari PA. 2013. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med 19: 626-630.
149. + lymphocyte density in pancreatic cancer correlates with lymph node metastasis. PLoS One 9: e106741.
150. Johnston FM, Tan MC, Tan BR Jr, Porembka MR, Brunt EM, Linehan DC, Simon PO Jr, Plambeck-Suess S, Eberlein TJ, Hellstrom KE, et al. 2009. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 15: 6511-6518.
151. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
152. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, et al. 2009. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324: 217.
153. Joyce JA, Pollard JW. 2009. Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
154. Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, Zhang J, Weitz J, Chin L, Futreal A, et al. 2014. Identification of double- stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 289: 3869-3875.
155. Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, White EP, Thompson CB, Rabinowitz JD. 2013. Hypoxic and Rastransformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci 110: 8882-8887.
156. Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, et al. 2015. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res 75: 544-553.
157. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, et al. 2012. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142: 730-733 e739.
158. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, et al. 2014. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158: 185-197.
159. Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. 2011. C-Raf is required for the initiation of lung cancer by KRas(G12D). Cancer Discov 1: 128-136.
160. Karsli-Uzunbas G, Guo JY, Price S, Teng X, Laddha SV, Khor S, Kalaany NY, Jacks T, Chan CS, Rabinowitz JD, et al. 2014. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov 4: 914-927.
161. Keenan BP, SaengerY, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, et al. 2014. A listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 146: 1784-1794.e6.
162. Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien KA, et al. 2011. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 42: 36-49.
163. Kharaziha P, Ceder S, Li Q, Panaretakis T. 2012. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta 1826: 103-111.
164. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP. 2008. SWI/ SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol 28: 3457-3464.
165. Kim MJ, Woo SJ, Yoon CH, Lee JS, An S, Choi YH, Hwang SG, Yoon G, Lee SJ. 2011. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem 286: 12924-12932.
166. Kimmelman AC. 2011. The dynamic nature of autophagy in cancer. Genes Dev 25: 1999-2010.
167. Kimmelman AC. 2015. Metabolic dependencies in RAS-driven cancers. Clin Cancer Res 21: 1828-1834.
168. KimmelmanAC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, et al. 2008. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci 105: 19372-19377.
169. King TA, LiW, Brogi E, Yee CJ, Gemignani ML, Olvera N, Levine DA, Norton L, Robson ME, Offit K, et al. 2007. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol 14: 2510-2518.
170. Kloppel G. 2000. WHO classification of tumours. IARC Press, Lyon, France.
171. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al. 2013. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24: 589-602.
172. Kochenderfer JN, Rosenberg SA. 2013. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10: 267-276.
173. Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JPT, Pan FC, Akiyama H, Wright CV, Jensen K, et al. 2012. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22: 737-750.
174. Kroemer G, Marino G, Levine B. 2010. Autophagy and the integrated stress response. Mol Cell 40: 280-293.
175. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, et al. 2012. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18: 1503-1510.
176. Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V,O'Dwyer KM, et al. 2013. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12: 329-341.
177. Laheru D, Jaffee EM. 2005. Immunotherapy for pancreatic cancer -science driving clinical progress. Nat Rev Cancer 5: 459-467.
178. Laoui D, Van Overmeire E, Movahedi K, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA. 2011. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology 216: 1192-1202.
179. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang CV. 2010. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci 107: 2037- 2042.
180. Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, et al. 2013. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 36: 382-389.
181. LeDT,Wang-GillamA, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, et al. 2015. Safety and survival with GVAX pancreas prime and listeria monocytogenes- expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33: 1325-1333.
182. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO. 2007a. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 109: 1561-1569.
183. Lee MG, Villa R, Trojer P, Norman J, Yan KP, Reinberg D, Di Croce L, Shiekhattar R. 2007b. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 318: 447-450.
184. LeeDW, Barrett DM, Mackall C, Orentas R, Grupp SA. 2012. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res 18: 2780- 2790.
185. Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, et al. 2014. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci 111: E3091-E3100.
186. Lee KE, Spata M, Bayne LJ, Buza EL, DurhamAC, Allman D, Vonderheide RH, Simon MC. 2015. Hif1α deletion reveals proneoplastic function of B cells in pancreatic neoplasia. Cancer Discov doi: 10.1158/2159-8290.CD-15-0822.
187. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, Yoshimura A, Reindl W, Sipos B, Akira S, et al. 2011. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19: 456-469.
188. Li J, Zhang Z, Dai Z, Plass C, Morrison C, Wang Y, Wiest JS, AndersonMW, You M. 2003. LOHof chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene 22: 1243-1246.
189. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. 2007. Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
190. Lim K-H, Counter CM. 2005. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8: 381-392.
191. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM. 2005. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 7: 533-545.
192. Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM. 2006. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 16: 2385-2394.
193. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. 2012. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
194. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, et al. 2015. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 47: 250-256.
195. Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, et al. 2014. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 74: 1924-1932.
196. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, Peng B, Fleming JB, Wang H, et al. 2012. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21: 105-120.
197. Lisanti MP, Martinez-Outschoorn UE, Sotgia F. 2013. Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and 'fibroblast addiction' are new therapeutic targets for drug discovery. Cell Cycle 12: 2723-2732.
198. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. 2009. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9: 445-452.
199. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, Debnath J. 2011. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 22: 165-178.
200. Lord CJ, Ashworth A. 2012. The DNA damage response and cancer therapy. Nature 481: 287-294.
201. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, et al. 2014. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2: 616-631.
202. Maddipati R, Stanger BZ. 2015. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov 5: 1086-1097.
203. Maitra A, Hruban RH. 2008. Pancreatic cancer. Annu Rev Pathol 3: 157-188.
204. Maitra A, Leach SD. 2012. Disputed paternity: the uncertain ancestry of pancreatic ductal neoplasia. Cancer Cell 22: 701-703.
205. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, Levy P, Ruszniewski P. 2002. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 51: 849-852.
206. Mann KM,Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, Brett BT, Sheetz TE, Dupuy AJ, Australian Pancreatic Cancer Genome Initiative, et al. 2012. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci 109: 5934-5941.
207. Mantovani A, Sica A. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22: 231-237.
208. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
209. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686.
210. Martin TD, Chen XW, Kaplan RE, Saltiel AR,Walker CL, Reiner DJ, Der CJ. 2014. Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion. Mol Cell 53: 209-220.
211. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S,HwuP, RestifoNP, OverwijkWW, Dong C. 2009. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787-798.
212. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. 2014. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514: 54-58.
213. Matthaei H, Schulick RD, Hruban RH, Maitra A. 2011. Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol 8: 141-150.
214. Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, et al. 2014. SMYD3 links lysine methylation of MAP3K2 to Rasdriven cancer. Nature 510: 283-287.
215. Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sanchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, et al. 2015. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med 21: 1163- 1171.
216. McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, et al. 2014. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25: 621-637.
217. McCormick F. 2015. KRAS as a therapeutic target. Clin Cancer Res 21: 1797-1801.
218. McMahon HT, Boucrot E. 2011. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 12: 517-533.
219. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, et al. 2014. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26: 707-721.
220. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, et al. 2015. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523: 177-182.
221. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. 2015. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121: 269-275.
222. Miron N, Miron MM, Milea VG, Cristea V. 2010. Proinflammatory cytokines: an insight into pancreatic oncogenesis. Roum Arch Microbiol Immunol 69: 183-189.
223. Mirus JE, Zhang Y, Li CI, Lokshin AE, Prentice RL, Hingorani SR, Lampe PD. 2015. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. Clin Cancer Res 21: 1764-1771.
224. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, et al. 2013. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 73: 1128-1141.
225. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H. 2012. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22: 66-79.
226. Mitsushita J, Lambeth JD, Kamata T. 2004. The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res 64: 3580-3585.
227. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
228. + regulatory T cells in a murine model of pancreas cancer. J Immunother 32: 12-21.
229. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. 2013. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 25: 230-237.
230. Morris JPT, Wang SC, Hebrok M. 2010. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10: 683-695.
231. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, et al. 2010. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res 70: 5728-5739.
232. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. 2005. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319.
233. Muller FL, Aquilanti EA, DePinho RA. 2015. Collateral lethality: a new therapeutic strategy in oncology. Trends Cancer 1: 161-173.
234. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, et al. 2011. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 71: 5101-5110.
235. Murphy SJ, Hart SN, Lima JF, Kipp BR, Klebig M, Winters JL, Szabo C, Zhang L, Eckloff BW, Petersen GM, et al. 2013. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 145: 1098-1109.e1.
236. Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. 2012. EGF receptor signaling is essential for kras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22: 318-330.
237. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, et al. 2011. Stromal biology and therapy in pancreatic cancer. Gut 60: 861-868.
238. Neesse A, Algul H, Tuveson DA, Gress TM. 2015. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut 64: 1476-1484.
239. Neufeld TP. 2010. TOR-dependent control of autophagy: biting the hand that feeds. Curr Opin Cell Biol 22: 157-168.
240. Nie Z, Hu G,Wei G, Cui K, Yamane A, ReschW,Wang R, Green DR, Tessarollo L, Casellas R, et al. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68-79.
241. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al. 2011. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17: 1498-1503.
242. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al. 2007. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13: 2151-2157.
243. + regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 99: 1188-1199.
244. Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, Zambirinis CP, Fallon NC, Rehman A, Pylayeva-Gupta Y, et al. 2012. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 209: 1671-1687.
245. Ohsawa S, Sato Y, Enomoto M, Nakamura M, Betsumiya A, Igaki T. 2012. Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. Nature 490: 547-551.
246. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
247. Orkin SH, Hochedlinger K. 2011. Chromatin connections to pluripotency and cellular reprogramming. Cell 145: 835-850.
248. Ostrand-Rosenberg S. 2008. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18: 11-18.
249. Ostrand-Rosenberg S. 2010. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59: 1593-1600.
250. Ostrem JM, Peters U, Sos ML,Wells JA, Shokat KM. 2013. K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503: 548-551.
251. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al. 2014. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25: 719-734.
252. PalmW, Park Y,Wright K, Pavlova NN, Tuveson DA, Thompson CB. 2015. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell 162: 259-270.
253. Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.
254. Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, Lengrand J, Deshpande V, Selig MK, Ferrone CR, et al. 2015. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature 524: 361-365.
255. Perez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. 2012a. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142: 1079-1092.
256. Perez-Mancera PA, Rust AG, van derWeyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grutzmann R, Aust D, Rummele P, et al. 2012b. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486: 266-270.
257. Phillips PA, McCarroll JA, Park S, Wu MJ, Pirola R, Korsten M, Wilson JS, ApteMV. 2003. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut 52: 275-282.
258. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. 2013. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 14: 765-780.
259. Pollard JW. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
260. Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, Gillanders WE, Linehan DC, Goedegebuure P. 2012. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother 61: 1373-1385.
261. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
262. Prior IA, Lewis PD, Mattos C. 2012. A comprehensive survey of Ras mutations in cancer. Cancer Res 72: 2457-2467.
263. Propper D, Davidenko I, Bridgewater J, Kupcinskas L, Fittipaldo A, Hillenbach C, Klughammer B, Ducreux M. 2014. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Ann Oncol 25: 1384-1390.
264. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. 2012. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418-429.
265. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. 2012. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21: 836-847.
266. Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov S, Bar-Sagi D. 2015. IL-35 producing B cells promote the development of pancreatic neoplasia. Cancer Discov doi: 10.1158/2159-8290.CD-15-0843.
267. Qiu W, Sahin F, Iacobuzio-Donahue CA, Garcia-Carracedo D, Wang WM, Kuo CY, Chen D, Arking DE, Lowy AM, Hruban RH, et al. 2011. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2: 862-873.
268. Qiu W, Tang SM, Lee S, Turk AT, Sireci AN, Qiu A, Rose C, Xie C, Kitajewski J, Wen HJ, et al. 2016. Loss of activin receptor type 1B accelerates development of intraductal papillary mucinous neoplasms in mice with activated KRAS. Gastroenterology 150: 218-228.
269. Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, Rhim A, Zhao L, ZhengW, Lightfoot S, et al. 2015. Doublecortin- like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PLoS One 10: e0118933.
270. Rabinowitz JD, White E. 2010. Autophagy and metabolism. Science 330: 1344-1348.
271. Racker E, Resnick RJ, Feldman R. 1985. Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc Natl Acad Sci 82: 3535-3538.
272. Raimondi S, Maisonneuve P, Lowenfels AB. 2009. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6: 699-708.
273. Rajeshkumar NV, Dutta P, Yabuuchi S, de Wilde RF, Martinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK, Hidalgo M, et al. 2015. Therapeutic targeting of theWarburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Res 75: 3355-3364.
274. Rebours V, Gaujoux S, d'Assignies G, Sauvanet A, Ruszniewski P, Levy P, Paradis V, Bedossa P, Couvelard A. 2015. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clin Cancer Res 21: 3522-3528.
275. Rhim AD, Stanger BZ. 2010. Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. Prog Mol Biol Transl Sci 97: 41-78.
276. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al. 2012. EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-361.
277. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, et al. 2014a. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25: 735-747.
278. Rhim AD, Thege FI, Santana SM, Lannin TB, Saha TN, Tsai S, Maggs LR, Kochman ML, Ginsberg GG, Lieb JG, et al. 2014b. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology 146: 647-651.
279. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. 2010. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28: 4769-4777.
280. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, et al. 2012. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2: 41-46.
281. Rodriguez PC, Ochoa AC. 2006. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol 16: 66-72.
282. Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, Sundsbak R, Shapiro V, Muders MH, Smyrk T, et al. 2011. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 140: 1303-1313.e3.
283. Roy R, Chun J, Powell SN. 2012. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12: 68-78.
284. Roy N, Malik S, Villanueva KE, Urano A, Lu X, Von Figura G, Seeley ES, DawsonDW, Collisson EA, Hebrok M. 2015. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Genes Dev 29: 658-671.
285. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. 2010. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33: 828-833.
286. Ryan DP, Hong TS, Bardeesy N. 2014. Pancreatic adenocarcinoma. N Engl J Med 371: 1039-1049.
287. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. 2013. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10: 423-433.
288. Salih DA, Brunet A. 2008. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol 20: 126-136.
289. Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M, Barneda D, Sellers K, Campos-Olivas R, Grana O, et al. 2015. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab 22: 590-605.
290. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, et al. 2015. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 6: 7686.
291. Scheede-Bergdahl C, Watt HL, Trutschnigg B, Kilgour RD, Haggarty A, Lucar E, Vigano A. 2012. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin Nutr 31: 85-88.
292. Schieber M, Chandel NS. 2014. ROS function in redox signaling and oxidative stress. Curr Biol 24: R453-R462.
293. Schonleben F, Qiu W, Ciau NT, Ho DJ, Li X, Allendorf JD, Remotti HE, Su GH. 2006. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 12: 3851-3855.
294. Schumacher TN, Schreiber RD. 2015. Neoantigens in cancer immunotherapy. Science 348: 69-74.
295. Serafini P, Borrello I, Bronte V. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65.
296. Settembre C, Fraldi A, Medina DL, Ballabio A. 2013. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 14: 283-296.
297. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A, Pollack JR. 2012. Convergent structural alterations define Switch/sucrose nonfermentable (SWI/ SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci 109: E252-E259.
298. Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS, deRooij DG, Hirsch S, Ravi K, Hicks JB, et al. 2011. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 334: 525-528.
299. Shao DD, XueW, Krall EB, Bhutkar A, Piccioni F,Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et al. 2014. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158: 171-184.
300. Sharma P, Allison JP. 2015. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161: 205-214.
301. Shen J, Peng Y,Wei L, ZhangW, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih Ie M, et al. 2015. ARID1A deficiency impairs theDNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov 5: 752-767.
302. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, et al. 2014. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159: 80-93.
303. Shi C, Hong SM, Lim P, Kamiyama H, Khan M, Anders RA, Goggins M, Hruban RH, Eshleman JR. 2009. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res 7: 230-236.
304. Shibuya KC, Goel VK, XiongW, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, et al. 2014. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One 9: e96565.
305. Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, et al. 2013. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 19: 6183-6192.
306. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274: 1531-1534.
307. Singh SK, Ellenrieder V. 2013. Senescence in pancreatic carcinogenesis: from signalling to chromatin remodelling and epigenetics. Gut 62: 1364-1372.
308. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J. 2009. A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489-500.
309. Singh H, Longo DL, Chabner BA. 2015. Improving prospects for targeting RAS. J Clin Oncol 33: 3650-3659.
310. Sipos B, Frank S, Gress T, Hahn S, Kloppel G. 2009. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 9: 45-54.
311. Siveke JT, Einwachter H, Sipos B, Lubeseder-Martellato C, Kloppel G, Schmid RM. 2007. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12: 266-279.
312. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, et al. 2010. Germline Brca2 heterozygosity promotes Kras (G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 18: 499-509.
313. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. 2010. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 29: 243-248.
314. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, et al. 2013. Glutamine supports pancreatic cancer growth through a KRASregulated metabolic pathway. Nature 496: 101-105.
315. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. 2008. Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
316. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, Swigart LB, Evan GI. 2013. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 27: 504-513.
317. Sousa CM, Kimmelman AC. 2014. The complex landscape of pancreatic cancer metabolism. Carcinogenesis 35: 1441- 1450.
318. Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D, Hingorani SR, Palculict TB, Izzo J, et al. 2013. Hypoxia triggers hedgehog-mediated tumor- stromal interactions in pancreatic cancer. Cancer Res 73: 3235-3247.
319. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. 2010. Myeloid-derived suppressor cells inhibit Tcell activation by depleting cystine and cysteine. Cancer Res 70: 68-77.
320. Staffas A, Karlsson C, Persson M, Palmqvist L, Bergo MO. 2015. Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice. Leukemia 29: 1032-1040.
321. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290.
322. Strobel O, Dor Y, Alsina J, Stirman A, Lauwers G, Trainor A, Castillo CF,WarshawAL, Thayer SP. 2007. In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology 133: 1999-2009.
323. Strober S. 1984. Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships. Annu Rev Immunol 2: 219-237.
324. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, McMahon M, White E. 2013. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 3: 1272-1285.
325. Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR. 2014. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63: 1769-1781.
326. Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen HN, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD, et al. 2015. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28: 638-652.
327. Sun Q, Phan J, Friberg AR, Camper DV, Olejniczak ET, Fesik SW. 2014. A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand. J Biomol NMR 60: 11-14.
328. Swanson JA, Watts C. 1995. Macropinocytosis. Trends Cell Biol 5: 424-428.
329. + T cells and dendritic cells in vivo. Jf Exp Med 203: 505-511.
330. Taki K, Ohmuraya M, Tanji E, Komatsu H, Hashimoto D, Semba K, Araki K, Kawaguchi Y, Baba H, Furukawa T. 2015. GNAS and Kras cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm. Oncogene doi: 10.1038/onc.2015.294.
331. + T cell immunity is impaired in pancreatic carcinoma patients. J Immunol 181: 6595-6603.
332. Thompson D, Easton DF, Breast Cancer Linkage Consortium. 2002. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358-1365.
333. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE. 1996. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13: 117-119.
334. Tjomsland V, Niklasson L, Sandstrom P, Borch K, Druid H, Bratthall C, Messmer D, Larsson M, Spangeus A. 2011. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol 2011: 212810.
335. To MD, Rosario RD, Westcott PM, Banta KL, Balmain A. 2013. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene 32: 4028-4033.
336. Toole BP. 2004. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539.
337. Trachootham D, LuW, Ogasawara MA, Nilsa RD, Huang P. 2008. Redox regulation of cell survival. Antioxid Redox Signal 10: 1343-1374.
338. Uhlirova M, Jasper H, Bohmann D. 2005. Non-cell-autonomous induction of tissue overgrowth by JNK/Ras cooperation in a Drosophila tumor model. Proc Natl Acad Sci 102: 13123- 13128.
339. Vander Heiden MG. 2013. Exploiting tumor metabolism: challenges for clinical translation. J Clin Invest 123: 3648-3651.
340. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
341. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS. 2004. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 279: 34643-34654.
342. Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM, et al. 2013. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23: 287-301.
343. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, et al. 2014. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514: 628-632.
344. Viale A, Corti D, Draetta GF. 2015. Tumors and mitochondrial respiration: a neglected connection. Cancer Res 75: 3687-3691.
345. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. 2011. Pancreatic cancer. Lancet 378: 607-620.
346. von Figura G, Fukuda A, Roy N, Liku ME, Morris Iv JP, Kim GE, Russ HA, Firpo MA, Mulvihill SJ, Dawson DW, et al. 2014. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol 16: 255-267.
347. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. 2013. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703.
348. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al. 2015. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518: 495-501.
349. Wahlgren J, De LKT, Brisslert M, Vaziri Sani F, Telemo E, Sunnerhagen P, Valadi H. 2012. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 40: e130.
350. Wang F, Permert J. 2002. Specific amino acid profile in culture media conditioned by human pancreatic cancer cell lines. Pancreatology 2: 402-406.
351. Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PT, Roberts CW. 2009. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res 69: 8094-8101.
352. Wang H, Maitra A, Wang H. 2015a. Obesity, intrapancreatic fatty infiltration, and pancreatic cancer. Clin Cancer Res 21: 3369-3371.
353. Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. 2015b. K-Ras promotes tumorigenicity through suppression of non-canonical wnt signaling. Cell 163: 1237-1251.
354. Ward PS, Thompson CB. 2012. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21: 297-308.
355. Watanabe T, Semba S, Yokozaki H. 2011. Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells. Br J Cancer 104: 146-154.
356. Wehr AY, Furth EE, Sangar V, Blair IA, Yu KH. 2011. Analysis of the human pancreatic stellate cell secreted proteome. Pancreas 40: 557-566.
357. Wei H,Wei S, Gan B, Peng X, ZouW, Guan JL. 2011. Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev 25: 1510-1527.
358. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. 2010. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci 107: 8788-8793.
359. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, Rabinowitz JD, Coller HA, Thompson CB. 2010. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 24: 2784-2799.
360. White E. 2013. Exploiting the bad eating habits of Ras-driven cancers. Genes Dev 27: 2065-2071.
361. White E. 2015. The role for autophagy in cancer. J Clin Invest 125: 42-46.
362. Williford JM, Wu J, Ren Y, Archang MM, Leong KW, Mao HQ. 2014. Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng 16: 347-370.
363. Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, Hahn WC, RobertsCW. 2014. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol 34: 1136-1144.
364. Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, Brody JR. 2008. Expression of indoleamine 2,3- dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 206: 849-854.
365. Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, et al. 2015. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6: 6744.
366. Wu MC, Arimura GK, Yunis AA. 1978. Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase. Int J Cancer 22: 728-733.
367. Wu J, Jiao Y, Dal Molin M, Maitra A, deWilde RF,Wood LD, Eshleman JR, Goggins MG,Wolfgang CL, Canto MI, et al. 2011a. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci 108: 21188-21193.
368. WuJ,Matthaei H, Maitra A, Dal MolinM,Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, et al. 2011b. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3: 92ra66.
369. Wu CY, Carpenter ES, Takeuchi KK, Halbrook CJ, Peverley LV, Bien H, Hall JC, DelGiorno KE, Pal D, Song Y, et al. 2014. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology 147: 1405-1416.e7.
370. Xu Z, Vonlaufen A, Phillips PA, Fiala-Beer E, Zhang X, Yang L, Biankin AV, Goldstein D, Pirola RC, Wilson JS, et al. 2010. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 177: 2585-2596.
371. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al. 2010. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
372. Yan C, Liu D, Li L,Wempe MF, Guin S, Khanna M, Meier J, Hoffman B, Owens C, Wysoczynski CL, et al. 2014. Discovery and characterization of small molecules that target the GTPase Ral. Nature 515: 443-447.
373. Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, Zhou Q. 2005. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 19: 535-545.
374. Yang S,Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell'antonio G, et al. 2011. Pancreatic cancers require autophagy for tumor growth. Genes Dev 25: 717-729.
375. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC, Von Hoff DD, Maitra A, Kimmelman AC. 2014. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov 4: 905-913.
376. Yee C. 2014. The use of endogenous T cells for adoptive transfer. Immunol Rev 257: 250-263.
377. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, et al. 2011. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov 1: 158-169.
378. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, et al. 2012. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149: 656-670.
379. Yuan TL, Fellmann C, Lee CS, Ritchie CD, ThaparV, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, et al. 2014. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov 4: 1182-1197.
380. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, et al. 2009. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325: 1555-1559.
381. Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, Anderson MW, Sills RC, Hong HL, Devereux TR, et al. 2001. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 29: 25-33.
382. Zhang Z, Jiang G, Yang F,Wang J. 2006. Knockdown of mutant Kras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. Cancer Biol Ther 5: 1481-1486.
383. Zhang Y, Gan B, Liu D, Paik JH. 2011. FoxO family members in cancer. Cancer Biol Ther 12: 253-259.
384. Zhang Y, Morris JPT, Yan W, Schofield HK, Gurney A, Simeone DM, Millar SE, Hoey T, Hebrok M, Pasca di Magliano M. 2013a. Canonical Wnt signaling is required for pancreatic carcinogenesis. Cancer Res 73: 4909-4922.
385. Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, Stanger BZ, Chung I, Rhim AD, di MaglianoMP. 2013b. Interleukin- 6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 73: 6359-6374.
386. ZhangW, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ,Wadhwa M, et al. 2014a. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal 7: ra42.
387. Zhang Y, McAllister F, Pasca di Magliano M. 2014b. Immune cells in pancreatic cancer: joining the dark side. Oncoimmunology 3: e29125.
388. + T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol Res 2: 423-435.
389. Zhao F, Obermann S, von Wasielewski R, Haile L, Manns MP, Korangy F, Greten TF. 2009. Increase in frequency of myeloid- derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 128: 141-149.
390. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. 2014. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74: 5057-5069.
391. Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens PI, et al. 2013. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497: 638-642.
392. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V, Buell U. 1997. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24: 678-682.
393. Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, et al. 2013. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci 110: 20723-20728.
394. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.